Leading change from the top line. Interview by Thomas A Stewart and David Champion.

Full Abstract

Most CEOs who specialize in turning around struggling companies focus on costs. But for Fred Hassan, chairman and CEO of Schering-Plough, the primary focus in a turnaround is the top line. Since 2003, when Hassan took the helm at the global pharmaceutical company, he has overseen a remarkable recovery in performance. And consistent with his philosophy, the turnaround started with sales. Considering sales reps as less than crucial to strategy, Hassan cautions, is a big mistake. At Schering-Plough, he has concentrated on motivating and organizing salespeople to create trusting relationships with doctors. "You have to differentiate the salesperson in the customer's mind--just like you differentiate brands," he explains. A doctor may see 60 pharmaceutical reps on a regular basis but actually trust far fewer. To earn a spot in this inner circle, Schering-Plough reps try to turn each customer encounter into an occasion to help doctors provide better care for their patients. Schering-Plough also restructured its sales forces so that reps carry not just one kind of product, as they do in most pharmaceutical companies, but several. Covering a broad range of treatments gives reps more ways to build value-adding relationships with doctors. In this interview, Hassan discusses his success at Schering-Plough and his experiences at other pharmaceutical companies. During his career, he has built a reputation for being in tune with the front lines, as well as for reaching out to the managers who supervise salespeople. He has found that this level of personal attention not only makes reps feel respected but also gives him valuable strategic insights.

Learn Faster Today Improve your study skills

Author information

Author/s: Hassan, Fred (F);

Journal and publication information

Publication Type: Interview

Journal: Harvard business review (Harv Bus Rev), published in United States. (Language: eng)

Reference: -2006 Jul-Aug; vol 84 (issue 7-8) : pp 90-7, 188

Dates: Created 2006/07/18; Completed 2006/08/01;

PMID: 16846192, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

These are the highest related articles currently in the database:

Guinea-pigging: healthy human subjects for drug safety trials are in demand. But is it a living? 5 Jan 2008
The business of RNAi therapeutics. 29 Apr 2008
Molecular Medicine TriConference 2008: bridging biology, chemistry, and business. 30 Dec 2007
Commercializing clinical trials--risks and benefits of the CRO boom. 2 Oct 2007
Entering the contract research industry in India. 4 Nov 2007
The truth about Prozac: an exchange. 12 Feb 2008
[History of insecticides and the transition of their production and sales] 30 Mar 2008
What's fueling the biotech engine? 29 Sep 2007
Pharmacy students' knowledge, attitudes, and evaluation of direct-to-consumer advertising. 13 Oct 2007
Business considerations in the development of probiotics. 30 Jan 2008

See 100+ related articles.